Literature DB >> 15814636

Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization.

Maro H Sandel1, Alisher R Dadabayev, Anand G Menon, Hans Morreau, Cornelis J M Melief, Rienk Offringa, Sjoerd H van der Burg, Connie M Janssen-van Rhijn, N Geeske Ensink, Rob A E M Tollenaar, Cornelis J H van de Velde, Peter J K Kuppen.   

Abstract

The clinical significance of tumor-infiltrating dendritic cells has been reported in a variety of human solid tumors as shown by the correlations found between the presence of tumor-infiltrating dendritic cells and clinical prognosis. In this study, we evaluated whether there is an association between the presence and maturation status of tumor-infiltrating dendritic cells, T lymphocytes, and clinical course in 104 primary tumor samples of patients with colorectal cancer. Dendritic cells were identified with four different markers (S-100, HLA class II, CD208, and CD1a) in double immunohistochemistry, with laminin as second marker to support the exact localization. Tumor-infiltrating dendritic cells showed a distinct infiltration pattern based on their maturation status. CD1a-positive dendritic cells resided in the advancing tumor margins in relatively high numbers, whereas mature CD208-positive dendritic cells were sparsely present in the tumor epithelium but mainly distributed in the tumor stroma and advancing tumor margin. Furthermore, high infiltration of CD1a-positive dendritic cells in the tumor epithelium was significantly correlated to the infiltration of CD4 lymphocytes (P = 0.006). Patients with relatively high numbers of mature CD208-positive infiltrating dendritic cells in the tumor epithelium had a shorter overall survival (P = 0.004). In addition, patients with relatively high numbers of CD1a-positive dendritic cells in the advancing margin of the tumor had a shorter disease-free survival (P = 0.03). We found that tumor-infiltrating dendritic cells had preferential infiltration sites within a tumor, affected local tumor cell-immune cell interactions, and correlated to the clinical prognosis of colorectal cancer patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814636     DOI: 10.1158/1078-0432.CCR-04-1448

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  61 in total

1.  Impact of tumor-infiltrating LAMP-3 dendritic cells on the prognosis of esophageal squamous cell carcinoma.

Authors:  Junya Nishimura; Hiroaki Tanaka; Yoshihito Yamakoshi; Soichiro Hiramatsu; Tatsuro Tamura; Takahiro Toyokawa; Kazuya Muguruma; Kiyoshi Maeda; Kosei Hirakawa; Masaichi Ohira
Journal:  Esophagus       Date:  2019-04-09       Impact factor: 4.230

2.  Quantification of blood dendritic cells in colorectal cancer patients during the course of disease.

Authors:  Giulia Orsini; Annalisa Legitimo; Alessandra Failli; Paola Ferrari; Andrea Nicolini; Roberto Spisni; Paolo Miccoli; Rita Consolini
Journal:  Pathol Oncol Res       Date:  2013-09-11       Impact factor: 3.201

3.  Role of dendritic cells in progression and clinical outcome of colon cancer.

Authors:  Maya V Gulubova; Julian R Ananiev; Tatyana I Vlaykova; Yovcho Yovchev; Vanya Tsoneva; Irena M Manolova
Journal:  Int J Colorectal Dis       Date:  2011-11-09       Impact factor: 2.571

4.  Microlocalization of CD68+ tumor-associated macrophages in tumor stroma correlated with poor clinical outcomes in oral squamous cell carcinoma patients.

Authors:  Yan-Hong Ni; Liang Ding; Xiao-Feng Huang; Ying-chun Dong; Qin-Gang Hu; Ya-Yi Hou
Journal:  Tumour Biol       Date:  2015-02-11

Review 5.  Dendritic cells and tumor microenvironment: a dangerous liaison.

Authors:  Ingo Fricke; Dmitry I Gabrilovich
Journal:  Immunol Invest       Date:  2006       Impact factor: 3.657

Review 6.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Authors:  Caroline Jochems; Jeffrey Schlom
Journal:  Exp Biol Med (Maywood)       Date:  2011-04-12

Review 7.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

8.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

Review 9.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

10.  Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer.

Authors:  Hester van Cruijsen; Mariëlle Gallegos Ruiz; Paul van der Valk; Tanja D de Gruijl; Giuseppe Giaccone
Journal:  BMC Cancer       Date:  2009-06-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.